Close menu

March 2nd, 2023 | 19:55 CET

Short-term 100% opportunity - Uranium is picking up: Global Atomic, Myriad Uranium, Rio Tinto

  • Mining
  • Uranium
  • nuclear
  • Investments
Photo credits:

Nuclear power as a discontinued model? Only ideologists with exclusively German glasses believe that! As of January 2023, new nuclear reactors are planned worldwide: In China, a whopping 47. In Russia 25, in India 12, the USA 3, Egypt 2 and so on. Even Japan, shaken by the Fukushima disaster, wants to connect a new nuclear power plant to the grid and believes in the safety of modern technology. We shed light on the uranium market and present a company with around 100% share price potential from a standing start.

time to read: 3 minutes | Author: Nico Popp

Table of contents:

    Rio Tinto: Prepares for uranium comeback

    The uranium market has been on the move in recent months. Many shares caused rapid price gains. Even established players, such as Rio Tinto, have recognized this. The Company used to make a significant share of its sales from uranium. In the past decade, however, uranium became less and less important - until the end of last year. Although Rio Tinto ceded its world-class Roughrider uranium project to US-based Uranium Energy Corp. at that time, it secured a stake in the entire company in return. For Rio Tinto, this move could pay off: Roughrider completes Uranium Energy Corp.'s existing portfolio in Canada's Athabasca Basin and makes large-scale production more likely. Thanks to Rio Tinto's stake in Uranium Energy Corp., the commodity multinational has a foot in the door to get back into the uranium business in a big way if needed, or at least to profit from it in the short term.

    The fact that a company like Rio Tinto indirectly holds shares in a North American uranium portfolio, even though most of the planned power plants are in other regions, can be seen as a vote of confidence in the uranium market. The uranium price also speaks a clear language: on a three-year horizon, the price of the coveted material has doubled but is still far below the level of the past uranium hype of 2006. For resourceful investors, the current market phase is exciting: uranium supply is low, and new projects must be measured against uranium prices between USD 25 and USD 50 - this provides enormous leverage in case uranium prices continue to rise and also a downside hedge for early investors.

    Global Atomic: Many have missed this "sixfold" increase

    The performance of Global Atomic shows what price movements around small uranium companies can look like when their story strikes a chord with investors. At the end of 2020, the share was still trading at EUR 0.50 - barely fourteen months later, it was trading at EUR 3.20. The share price has risen by a factor of six. Global Atomic is pushing ahead with its Dasa uranium project in the African state of Niger and also has a zinc project in Turkey. Niger, in particular, is an exciting hotspot for uranium mining. Traditionally, the French company Areva mined uranium there. Niger is also seen as a kind of beacon in the midst of politically unstable countries - among other things, the US operates its most important airbase in Africa there.

    Myriad Uranium: Super key data, mini valuation

    In addition to Global Atomic, GoviEx, ENRG Elements and Myriad Uranium are other smaller publicly traded companies exploring uranium in Niger. While Global Atomic is already valued at around CAD 700 million, the Australian company ENRG Elements has a valuation of just over CAD 20 million. Myriad Uranium weighs in at only about half of that - and that despite convincing key data. For example, Myriad Uranium controls more than 1,800 sq km of land, about 2.5 times more than ENRG Elements.

    It also looks as if Myriad Uranium has secured promising properties: The Azouza Fault geological fault, which features Global Atomic's Dasa mine, continues on Myriad's exploration property, as does the Arlit Fault, located near the Imouraren mine. After long preparatory work, the team around Myriad CEO Thomas Lamb, which in part has already led the cobalt company M2 Cobalt to a successful exit, succeeded in securing the exploration rights around uranium in Niger last year. The terms agreed at the time date back to more geopolitically stable times and are considered favourable, according to Myriad CEO Lamb. Myriad is counting on cooperation with local company Loxcroft, Myriad Uranium's largest shareholder alongside management, to develop its uranium properties.

    Is this a 100% opportunity?

    Along with the exploration rights, the Company gained access to 24,000 meters of historical drill samples and other geomagnetic survey results from when the French Areva Group operated in the region. Special detail: Large parts of Myriad's properties have been earmarked by Areva for intensive exploration work. The plans for this are also available to Myriad. From today's perspective, the shares of Myriad Uranium could offer promising opportunities - competitor ENRG Elements is currently about twice as expensive despite a significantly smaller land area. Since Myriad Uranium has an experienced team of geologists and company builders with experience in Africa, speculative investors should keep the stock, currently valued at only about CAD 10 million, on their radar. Companies like Myriad Uranium have been in the spotlight at commodity conferences, such as the recent Mining Indaba in Cape Town, South Africa. A short interview is available online.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by Nico Popp on September 28th, 2023 | 09:05 CEST

    Germany - Car Country? The exodus begins: Mercedes-Benz, Volkswagen, First Phosphate

    • Mining
    • phosphate
    • Electromobility
    • Energy

    Cars still play a significant role in Germany. Many households have two vehicles, some even more. However, sales of new cars have weakened recently - the question of whether to buy a combustion engine or an electric vehicle, along with inflation, have deterred many buyers. German brand manufacturers are now being attracted to the US. There, they are enticed by subsidies and an intact market. Find out what the latest plans of Mercedes-Benz, Volkswagen, and others entail and which relatively unknown company could benefit.


    Commented by André Will-Laudien on September 28th, 2023 | 08:05 CEST

    Attention: Extended correction - Buy the right stocks now! Bayer, Viva Gold, TUI, and BASF are on the list!

    • Mining
    • Gold
    • Pharma
    • chemicals
    • travel

    Higher inflation and rising interest rates - this connection should be clear to investors. The interest rate level in Germany has moved from negative territory to 2.77% in the 10-year range, but stocks continued to rise cheerfully. The party led to all-time highs of 16,528 points in July, but the fundamental situation of the companies deteriorated in parallel. Only after repeated warnings from the US Federal Reserve did the explosive NASDAQ also enter a correction. And it continues. Yesterday, the CEO of US investment bank JPMorgan, Dimon, warned that the world may not be prepared for 7% capital market interest rates. He and Dr. Jens Erhardt, the CEO of the asset management company DJE, warn of stronger setbacks on the stock markets. Some stocks have already undergone a strong correction. Here is a brief overview.